Geneticure

What Geneticure does

Geneticure, Inc. is a precision medicine company headquartered in Rochester, Minnesota (incorporated in Minnesota, 2014/2016) that has developed a patented pharmacogenomic test for hypertension treatment selection. The test uses a cheek-swab DNA sample to analyze 17 genotypes across 11 genes via a patent-pending multi-gene algorithm, producing a personalized report that ranks blood pressure medications based on predicted responsiveness across three organ systems (cardiac, vascular, renal). Clinical evidence cited by the company includes a 2019 Journal of Clinical Medicine study showing approximately 7mmHg lower systolic and 6mmHg lower diastolic blood pressure with DNA-guided therapy versus non-genetically matched care (22% and 39% reductions respectively), with downstream modeling suggesting 40% stroke reduction and 25% heart attack reduction.

The company's commercial model is built around physician-ordered testing: tests cannot be purchased directly by consumers and must be ordered by a healthcare provider who verifies NPI credentials and submits the order. The test is sold on a self-pay basis with pricing not publicly disclosed, and Geneticure does not support direct insurance reimbursement but allows patients to independently submit claims. Sample processing is handled through a contractual CAP-accredited laboratory in Arizona, and Geneticure itself operates a CLIA-certified lab (CLIA 24D2145318) under HIPAA-compliant data handling. Notable investors include Mayo Clinic, Stanford University, Fairview Health, Wireframe Ventures, M25, Southeast Minnesota Capital Fund, and the University of St. Thomas. Beyond the core hypertension panel, Geneticure has pipeline products including a Renal Denervation Prediction Panel and a COVID-19 severity test, both leveraging the same RAAS-related genetic platform. The company serves the US market (with New York State excluded) and employs 1–10 people, with cumulative disclosed funding of approximately $5.97M across six rounds from 2016 to 2022.

Name

Geneticure

Legal name

Geneticure, Inc.

Website

https://geneticure.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Geneticure is a precision medicine company that sells a patented cheek-swab pharmacogenomic test analyzing 17 genotypes across 11 genes to recommend personalized blood pressure medications for hypertension patients, distributed exclusively through physician-ordered channels on a self-pay basis.

Ownership category

akta.pro rank

Product category

Pharmacogenomic Diagnostic Testing

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Pharmacogenomics-Informed Medication Optimization Support (HSABALAO), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Pharmacogenomic testing
• Hypertension treatment
• DNA-guided therapy
• Personalized medicine
• Genetic diagnostic tests

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: Geneticure generates revenue through the sale of its DNA-based pharmacogenomic test for hypertension treatment optimization. The test is physician-ordered and paid for by patients (self-pay) or potentially through insurance reimbursement submission. The company does not currently support direct insurance coverage but allows patients to independently submit claims to their insurance companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Geneticure sells a patented pharmacogenomic test kit that uses a cheek-swab DNA sample to analyze 17 genotypes across 11 genes, generating a personalized ranking of blood pressure medications most likely to lower an individual's blood pressure. The test must be ordered by an authorized healthcare provider and is processed by a CLIA-certified lab with CAP-accredited partners, delivering a report to both patient and ordering physician. Pricing is one-time self-pay, with patients able to independently submit claims to insurance for potential reimbursement.

Product overview

Geneticure offers a portfolio of pharmacogenomic testing products centered on its proprietary multi-gene algorithm. The core product is the Hypertension Pharmacogenomic Panel, a cheek-swab DNA test that analyzes 17 genotypes across 11 genes to generate personalized blood pressure medication recommendations. This test is complemented by pipeline offerings including the Renal Denervation Panel (which applies the same algorithm approach to predict renal denervation response) and a COVID-19 solution (which adapts the platform to predict ACE2 levels and COVID-19 severity). All products share the same genetic testing infrastructure and multi-system analytical approach.

Differentiator

Problem solved

Functional benefit

Products and services

• Geneticure Hypertension Pharmacogenomic Panel A cheek-swab DNA pharmacogenomic test that analyzes 17 genotypes across 11 genes to predict which blood pressure medications will work best for an individual patient, generating a personalized ranked medication report based on three organ systems (cardiac, vascular, renal). The test must be ordered by an authorized healthcare provider, is processed in a CLIA-certified laboratory with CAP-accredited partners, and is sold on a one-time self-pay basis with optional patient-initiated insurance claim submission.
• Geneticure for Renal Denervation Panel A genetic screening test designed to identify patients who will respond to renal denervation procedures, assessing genotypes across SNS, cardiac, RAAS, and renal systems to predict treatment responders and non-responders. Targeted at clinicians evaluating patient candidacy for renal denervation as a hypertension intervention.
• Geneticure COVID-19 Solution A cheek-swab test application leveraging the existing genetic platform to identify patients with low vs. high ACE2 levels and predict COVID-19 severity and treatment response using RAAS genetic variants. Intended as a secondary application of Geneticure's underlying pharmacogenomic testing capability.

Quantifiable outcome

• 22% lower systolic blood pressure compared to non-genetically matched care
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CAP-Accredited Laboratory (Arizona)coreTechnology or IntegrationGeneticure contracts with clinical testing laboratories accredited by the College of American Pathologists (CAP) for DNA extraction, genotyping, and processing. Samples are transferred to this third-party laboratory in Arizona for processing.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genelex: Genelex is a pharmacogenomics laboratory offering PGx testing for multiple drug classes including cardiovascular medications. It is a direct competitor in the PGx testing space with similar physician-ordered testing workflows and CLIA-certified lab operations.
• OneOme: OneOme is a pharmacogenomics company offering the RightMed test that analyzes genetic variants to predict drug response across multiple therapeutic areas. It is the most directly comparable peer to Geneticure given its focus on PGx testing using DNA samples with physician-ordered delivery and clinical evidence-based positioning.
• Assurex Health (now Myriad): Assurex Health (now part of Myriad Genetics as GeneSight) developed pharmacogenomic tests for mental health medications using similar Mayo Clinic-originated technology. Geneticure's advisor Don Wright led Assurex's growth to ~500 employees, suggesting similar scaling pathways for Geneticure.

Broad incumbents

• GeneDx (Sema4): GeneDx (now part of Sema4) is a clinical genetic testing laboratory offering a broad range of genetic tests. As an established lab with CLIA/CAP credentials and payer relationships, it represents a potential competitor if it expands into cardiovascular PGx.
• Invitae: Invitae is a large genetic testing company offering a broad menu of genetic tests including some pharmacogenomic offerings. It represents an incumbent that could expand into hypertension PGx with greater resources and existing payer relationships.
• Veracyte: Veracyte is a specialized genomic diagnostics company focused on improving outcomes in cancer and other diseases through molecular testing. While focused on different therapeutic areas, it serves as a relevant comparable for a clinically validated, evidence-based genomic testing company model.
• Myriad Genetics: Myriad Genetics is a large established genetic testing company that acquired Assurex Health (a Mayo Clinic spinout PGx company) in 2016. It serves as a broad incumbent offering hereditary cancer testing, pharmacogenomics (GeneSight), and other genetic tests, and represents both a competitive threat and a potential acquirer.

Emerging players

• 23andMe: 23andMe is a consumer genetic testing company that Geneticure explicitly references as a comparison point (noting their tests are 'unlike general genetic tests'). 23andMe represents an alternative consumer genetic testing model that could expand into therapeutic-area PGx over time.
• Color Health: Color Health is a genetic testing company offering hereditary cancer and other genetic tests with a focus on affordability and population-scale screening. While primarily focused on different indications, it represents an emerging platform approach to genetic testing that could compete for the same clinical workflow integration.

Others

• Ancestry: Ancestry is a consumer genetic testing company focused on genealogy that Geneticure explicitly distinguishes itself from. While not a direct competitor in PGx, Ancestry represents the broader consumer genetic testing ecosystem that Geneticure references as a baseline comparison for its clinical-grade hypertension-specific test.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/geneticure
• LinkedInlinkedin.com/company/geneticure
• Facebookfacebook.com/geneticure

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneticure